Taysha Gene Therapies Inc (TSHA) - Total Liabilities
Based on the latest financial reports, Taysha Gene Therapies Inc (TSHA) has total liabilities worth $97.56 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Taysha Gene Therapies Inc cash flow conversion to assess how effectively this company generates cash.
Taysha Gene Therapies Inc - Total Liabilities Trend (2019–2024)
This chart illustrates how Taysha Gene Therapies Inc's total liabilities have evolved over time, based on quarterly financial data. See TSHA net assets for net asset value and shareholders' equity analysis.
Taysha Gene Therapies Inc Competitors by Total Liabilities
The table below lists competitors of Taysha Gene Therapies Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
HannStar Board Corp
TW:5469
|
Taiwan | NT$57.47 Billion |
|
Eit Environmental Development Group
SHE:300815
|
China | CN¥4.97 Billion |
|
Advtech
JSE:ADH
|
South Africa | ZAC4.68 Billion |
|
Guild Holdings Co
NYSE:GHLD
|
USA | $3.86 Billion |
|
FAWER Automotive Parts Ltd Co
SHE:000030
|
China | CN¥9.06 Billion |
|
JinkoSolar Holding Company Limited
NYSE:JKS
|
USA | $90.73 Billion |
|
Sunonwealth Electric Machine Industry Co Ltd
TW:2421
|
Taiwan | NT$7.31 Billion |
Liability Composition Analysis (2019–2024)
This chart breaks down Taysha Gene Therapies Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Taysha Gene Therapies Inc stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 10.48 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.45 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.31 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Taysha Gene Therapies Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Taysha Gene Therapies Inc (2019–2024)
The table below shows the annual total liabilities of Taysha Gene Therapies Inc from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $88.84 Million | -9.16% |
| 2023-12-31 | $97.79 Million | -21.97% |
| 2022-12-31 | $125.33 Million | +5.70% |
| 2021-12-31 | $118.57 Million | +1464.49% |
| 2020-12-31 | $7.58 Million | +4952.67% |
| 2019-12-31 | $150.00K | -- |
About Taysha Gene Therapies Inc
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-11… Read more